by Lauren Vamos, Operations Associate @ Power

In two months, a Mount Sinai research manager cut 25 hours of cold-outbound each week, booked three screening visits, and enabled more quality time to engage with patients. Kaitlyn Coyle sat down with Power to share how she redesigned her recruitment flow.

“I used to spend five hours per day filtering through hospital and clinic records and reaching out to people who I thought might qualify,” she explained. “That’s 75% of my time spent doing cold outreach.”

“If I texted a hundred patients, maybe 20 of them, get back to us, and then maybe two or three are eligible. So it's a lot of coordinator time.” And of those who are eligible, many are unwilling to stop their current treatment regimen, which is a requirement for this trial.

Kaitlyn decided to try Power to cut down on her cold outreach time. She discovered the platform because Power reached out to her about an interested participant. She was impressed by the minimal effort required on her part to bring in highly qualified referrals.

Kaitlyn and Power spent 20 minutes setting up her trial on the platform. After that, she hasn’t needed to do any work to find these referrals. Instead, she can devote more time to building rapport and educating highly qualified patients.

“Of the 30 or so Power referrals I’ve contacted over the last two months, 3 have come in for screening and one is about to be randomized. These three are 100% of my total screening visits,” she explained to us during a recent check-in.

“And it’s very easy. We see an email come in from Power with an interested patient. We reach out, we get a yes or a no, and that’s it. Everyone answers us, which is nice because most of the people we do our normal cold outreach to just don’t respond”.

Now, Kaitlyn can use more of her time to improve the experiences of participants. “We try to be very fun. We make the appointments fun. We don't want them to feel like they're coming to the hospital for an appointment.”

Another factor that demotivates patients is distance and travel time because the trial requires frequent in-person visits. But according to Kaitlyn, “we couldn’t pay attention to distance when we did cold outreach because it would take too long to look through every chart and figure out how far away they are.”

“Power is so helpful here because we get to filter a distance of where we want the patients to be.”

Kaitlyn’s trial is testing a new, non-addictive pain medication for neuropathy in Type II Diabetes. The goal of the trial is to reduce the burden of the opioid epidemic while continuing to alleviate pain in diabetes patients.

If approved, the medication will be tested for other conditions. Over time, the patients from Power will be part of a massive cohort paving the way for safer, non-addictive pain treatment.